RGDXQ (Response Genetics) Shares Buyback Ratio %: 64.81 (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Response Genetics Shares Buyback Ratio %?

Response Genetics RGDXQ -99.00% Shares Buyback Ratio % is 64.81 as of Aug. 20, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Response Genetics's current shares buyback ratio was 64.81%.

Response Genetics Shares Buyback Ratio % Related Terms

Response Genetics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Response Genetics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Shares Buyback Ratio % Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.44 -67.85 -18.03 -0.21 64.81

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 -0.16 0.00 64.81

Response Genetics Shares Buyback Ratio % Calculation

Response Genetics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2014 ) - Shares Outstanding (EOP) (A: Dec. 2015 )) / Shares Outstanding (EOP) (A: Dec. 2014 )
=(38.795 - 13.652) / 38.795
=64.81%

Response Genetics's Shares Buyback Ratio for the quarter that ended in Dec. 2015 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2015 ) - Shares Outstanding (EOP) (A: Dec. 2015 )) / Shares Outstanding (EOP) (A: Mar. 2015 )
=(38.795 - 13.652) / 38.795
=64.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 64.81 mean?
Response Genetics (RGDXQ) has a Shares Buyback Ratio % of 64.81 as of Aug. 20, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Response Genetics and its competitors.
Is Response Genetics' Shares Buyback Ratio % too high?
Response Genetics' current Shares Buyback Ratio % is 64.81.
How does Response Genetics' Shares Buyback Ratio % compare to PSID and GBSN?
Response Genetics' Shares Buyback Ratio % of 64.81 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Medical Diagnostics & Research company?
A good Shares Buyback Ratio % depends on the Medical Diagnostics & Research industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Response Genetics and its competitors. Response Genetics's current Shares Buyback Ratio % is 64.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Shares Buyback Ratio % of 64.81. The current Shares Buyback Ratio % is 64.81. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Shares Buyback Ratio % is 64.81 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.